CER-209

N/A

Report date: 2024/04/16 18:03:22
NME

Base Information

Drug NameCER-209
Drug Alias NameCER-209
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP2Y purinoceptor 13 agonists
TargetsP2Y purinoceptor 13
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCerenis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCerenis Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A